Disease relevance of SLC13A5

• The accuracy of MRS in detecting metastases was 75% in patients who received NACT (n=9) as compared to 96% in those who did not (n=21) [1].

Psychiatry related information on SLC13A5

• ASME/NACT meeting, 4 december 1998 making career choices - based on evidence [2].

High impact information on SLC13A5

• Whole-body clearance (CL) was 0.58 l kg(-1) h(-1) (95% CI 0.44-0.72) for reduced NAC (NACR) and 0.16 (0.13-0.20) l kg(-1) h(-1) for total NAC (NACT) [3].
• The mouse nact gene coding for the transporter is approx. 23 kb long and consists of 12 exons [4].
• All but one patient received a combination of bleomycin, etoposide, and cisplatin (BEP) either as neoadjuvant (NACT, 3 cases) or as adjuvant therapy (28 cases) [5].

Analytical, diagnostic and therapeutic context of SLC13A5

• Schedules of combined treatment more frequently represented by neoadjuvant chemotherapy followed by radiation (NACT) and by concomitant chemotherapy and radiation (CT-RT) [6].
• A 5-year disease-free survival rate for the NACT arm and CO arm, respectively, of 77.1% and 64.3% in Stages Ib-IIa (p < .05), 56.2% and 57.1% in Stage IIb (p = NS) was found [7].
• METHODS: Between 1991 and 1999, 131 patients with HNC, mostly stages III and IV, who had loco-regional residual ( n = 78) or recurrent lesions ( n = 53) following curative therapy with either radiotherapy (RT), neoadjuvant CT (NACT) followed by RT, or concurrent CTRT were included in this analysis [8].
• One hundred and fifty-six patients in Stage Ib-IIb (n = 86, NACT arm and n = 70, CO arm) and 16 patients in Stage III (NACT arm) who proved to be sensitive to the neoadjuvant chemotherapy, underwent radical hysterectomy [7].

References